BROOKLYN IMMUNOTHERAPEUTICS

Brooklyn ImmunoTherapeutics operates as a clinical-stage biopharmaceutical company. The Company discovers and develops a novel cytokine-based therapy to treat patients with cancer. Their advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2a clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. The IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. Brooklyn ImmunoTherapeutics serves patients and customers in the State of New York.

#SimilarOrganizations #People #Financial #Event #Website #More

BROOKLYN IMMUNOTHERAPEUTICS

Industry:

Biotechnology Health Care Pharmaceutical Therapeutics

Founded:

2018-09-27

Address:

New York, New York, United States

Country:

United States

Website Url:

http://www.brooklynitx.com

Total Employee:

11+

Status:

Active

Contact:

(212) 582-1199

Total Funding:

21.18 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network Google Universal Analytics

Similar Organizations

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Current Employees Featured

not_available_image

Susan McClatchey
Susan McClatchey Vice President and Head of Quality @ Brooklyn ImmunoTherapeutics
Vice President and Head of Quality

roger-sidhu_image

Roger Sidhu
Roger Sidhu Chief Medical Officer @ Brooklyn ImmunoTherapeutics
Chief Medical Officer
2021-09-20

not_available_image

Jay Sial
Jay Sial Chief Administrative Officer @ Brooklyn ImmunoTherapeutics
Chief Administrative Officer

matt-angel_image

Matt Angel
Matt Angel Interim Chief Executive Officer and President @ Brooklyn ImmunoTherapeutics
Interim Chief Executive Officer and President
2022-05-01

ron-guido_image

Ron Guido
Ron Guido Chief Development Officer @ Brooklyn ImmunoTherapeutics
Chief Development Officer
2021-04-01

andrew-jackson_image

Andrew Jackson
Andrew Jackson Chief Financial Officer @ Brooklyn ImmunoTherapeutics
Chief Financial Officer
2022-01-01

Stock Details

Company's stock symbol is NYSEMKT:BTX

Acquisitions List

Date	Company	Article	Price
2021-06-14	Novellus	Novellus acquired by Brooklyn ImmunoTherapeutics	125 M USD
2021-03-25	NTN Buzztime	NTN Buzztime acquired by Brooklyn ImmunoTherapeutics	N/A
2018-11-19	IRX Therapeutics	IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics	N/A

Key Employee Changes

Date	New article
2022-05-31	Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Po...
2021-11-29	Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality
2021-09-22	Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer
2021-07-13	Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer

Official Site Inspections

http://www.brooklynitx.com Semrush global rank: 3.11 M Semrush visits lastest month: 5.17 K

Host Informations
Whois Informations

Loading ...

America

Europe

Asia

Others

BROOKLYN IMMUNOTHERAPEUTICS

BROOKLYN IMMUNOTHERAPEUTICS

Industry:

Founded:

Address:

Country:

Website Url:

Total Employee:

Status:

Contact:

Total Funding:

Technology used in webpage:

Similar Organizations

Aimmune Therapeutics

Edgewise Therapeutics

Current Employees Featured

Stock Details

Acquisitions List

Key Employee Changes

Official Site Inspections

More informations about "Brooklyn ImmunoTherapeutics" on Search Engine